Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Técnica para la detección previa de septicemia

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20180226003
Publicado:
27/02/2018
Caducidad:
28/02/2019
Resumen:
Un centro de transferencia de tecnología de Reino Unido especializado en comercialización de tecnologías de seguridad y defensa ha desarrollado una nueva técnica de biotecnología para la detección temprana de septicemia en un paciente. Esta técnica, basada en un conjunto de biomarcadores, determina la presencia de la septicemia días antes de que aparezcan los síntomas clínicos, y permite diferenciar entre septicemia, síndrome de respuesta inflamatoria sistémica (SRIS) y controles negativos. La técnica es compatible con formatos RT-qPCR (reacción en cadena de la polimerasa cuantitativa en tiempo real) para obtener resultados rápidos. El centro busca fabricantes de herramientas de diagnóstico in vitro con el fin de establecer acuerdos de licencia.

Details

Tittle:
Technique for the pre-identification of sepsis is available for license
Summary:
A technology transfer organisation in the UK that specialises in the commercialisation of defence and security technology research is licensing a novel biotechnology technique allowing early identification of sepsis in a patient. Based on a set of biomarkers, it can determine the presence of sepsis days before clinical symptoms appear. The organisation is looking to offer its technology to manufacturers of in-vitro diagnostic tools under license agreements.
Description:
Diagnosed cases of sepsis exceed 18 million a year with 1,400 patients dying daily in the developed world. Rapid treatment is critical to a patient´s recovery and therefore the time taken to diagnose sepsis is key.
Sepsis is caused when a patient´s immune system overreacts to an infection. It is a potentially life-threatening condition which is responsible for 44,000 deaths each year in the UK alone. There are more deaths from sepsis than those from prostate cancer, breast cancer and AIDS combined.
If treated in time most patients have the potential to recover, however, current diagnosis of sepsis cannot be made until the patient demonstrates having symptoms. The test to identify the bacteria causing the infection is typically conducted using a microbial culture which may take two to four days to complete during which time the patient´s condition will deteriorate.
A leading UK technology transfer organisation has developed a new technique which is not dependent upon needing the symptoms of sepsis to be clinically displayed. Instead, a set of biomarkers are used in suspected patients to diagnose the presence of sepsis before the symptoms appear. A panel of 44 biomarkers has been identified following analysis of 3,255 post-surgery patient blood courses. The panel gives a predictive accuracy of at least 97% to differentiate between the development of sepsis from non-sepsis and 100% predictive accuracy in differentiating sepsis from Systemic Inflammatory Response Syndrome (SIRS).
This allows the determination of the patient´s condition and possible identification of sepsis much earlier, extending the treatment window and making it more effective.
The company is looking to offer the technology to manufacturers of in-vitro diagnostic tools under a license agreement.
Advantages and Innovations:
¿ Therapeutic window extended and mortality rates reduced
¿ Lower cost of treatment
¿ Can discriminate between sepsis, Systemic Inflammatory Response Syndrome (SIRS), and negative controls
¿ Compatible with RT-qPCR (Real-Time Quantitative Polymerase Chain Reaction) formats for rapid results
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
UK patent pending.

Partner sought

Type and Role of Partner Sought:
The company is looking to license out this new technique to interested manufacturers of in-vitro diagnostic tools.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001011 Enfermedades circulatorias y del corazón
06001013 Tecnología médica / ingeniería biomédica